Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$14.45M$14.45M+65.7% vs Q1 2025 Net Income-$8.06M-$8.06MN/M vs Q1 2025 EPS Diluted-$0.07-$0.07N/M vs Q1 2025 Operating Income-$4,204,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Free Cash Flowderived-$14,858,000N/M Margins · derivedOperating margin-29.1%+193.0 pt vs Q1 2025
Net margin-55.8%+207.2 pt vs Q1 2025
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end